Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Mind Medicine (MindMed) Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "PRODUCT CANDIDATE INDICATION PRE-CLINICAL PHASE 1 PHASE 2 PHASE 3 REGISTRATION"
08/14/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "LOAN AND SECURITY AGREEMENT This LOAN AND SECURITY AGREEMENT dated as of August 11, 2023 is entered into among MIND medicine INC., a corporation incorporated under the laws of the Province of British Columbia , and each other Person party hereto as a borrower set forth on Schedule 1 hereto from time to time , and each other Person party hereto or party to any other Loan Document as a guarantor from time to time , K2 HEALTHVENTURES LLC, as a lender, and the other lenders from time to time party hereto , K2 HEALTHVENTURES LLC, as administrative agent for Lenders and collateral agent for the Lenders under the Canadian Security Documents , and ANKURA TRUST COMPANY, LLC, as collateral trustee for Lenders . AGREEMENT Borrower Representative, each Loan Party from time to time party hereto, Admini..."
08/03/2023 8-K Quarterly results
Docs: "MindMed Reports Second Quarter 2023 Financial Results and Business Highlights – Topline readout of MM-120 in GAD expected in Q4 2023 with enrollment to be concluded in Q3 2023 – – Topline readout of MM-120 in ADHD anticipated in Q4 2023 / Q1 2024 – – MM-402 in ASD on track for Phase 1 clinical trial initiation in Q4 2023 – – Entered into exclusive license agreement with Catalent for MM-120 Zydis® orally disintegrating tablet formulation for advancement into pivotal clinical trials – – Cash and cash equivalents of $116.9 million at June 30, 2023 – – Company to host conference call today at 4:30 PM ET –"
06/16/2023 8-K Other Events  Interactive Data
05/24/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "MindMed to Present Data on the Preclinical Activity of MM-402 at the American Society of Clinical Psychopharmacology 2023 Annual Meeting – Preclinical data in ASD model demonstrate prosocial effects of MM-402 –"
05/17/2023 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "MindMed Announces Enrollment Milestone in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder – Over 50% of patients dosed across 20 active clinical sites – – On Track for Topline Results in late 2023 –"
05/04/2023 8-K Quarterly results
04/18/2023 8-K Quarterly results
04/18/2023 8-K Quarterly results
04/14/2023 8-K Quarterly results
03/13/2023 8-K Other Events  Interactive Data
03/09/2023 8-K Quarterly results
Docs: "99.1 MindMed Reports Full Year 2022 Financial Results and Business Highlights – Company positioned for key MM-120 Phase 2b data readout in GAD and Phase 2a data readout in ADHD in late 2023 – – Company to initiate first clinical trial of MM-402 in 2023 – – Cash and cash equivalents of $142.1 million at December 31, 2022 – – Company to host conference call today at 4:30 PM ET –"
01/09/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"MindMed Provides Corporate Update and 2023 Outlook"
09/29/2022 8-K Quarterly results
09/14/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"MindMed Announces Compliance with Nasdaq Listing Requirements"
08/26/2022 8-K Quarterly results
08/11/2022 8-K Quarterly results
07/21/2022 8-K Quarterly results
06/30/2022 8-K Quarterly results
06/02/2022 8-K Quarterly results
05/23/2022 8-K Quarterly results
05/19/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
Docs: "MindMed Reports First Quarter 2022 Financial Results and Business Highlights - Advanced clinical programs for three lead drug candidates - - Strengthened leadership team with the appointment of Francois Lilienthal, MD as Chief Commercial Officer - - Cash runway through key clinical readouts in 2023 and into 2024 - - Company to host conference call today at 8:30 AM ET -"
05/11/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"MindMed Collaborators Prof. Liechti and Dr. Holze Announce Positive Topline Data from Phase 2 Trial Evaluating LSD in Anxiety Disorders"
04/26/2022 8-K Investor presentation
Docs: "MindMed Corporate Overview, dated April 2022"
03/28/2022 8-K Quarterly results
Docs: "MindMed Reports Full Year 2021 Financial Results and Business Highlights - FDA cleared MindMed’s Investigational New Drug application for Phase 2b dose optimization trial of MM-120 - - Progressed development programs for all three lead product candidates - - Cash balance of $133.5 million at year end 2021 - - Company to host earnings conference call today at 8:30 AM EDT -"
03/25/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"MindMed Announces Transition of CFO"
02/23/2022 8-K Quarterly results
01/25/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "FDA Clears MindMed IND for MM-120 in Treatment of Generalized Anxiety Disorder"
01/07/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Stephen Hurst Resigns from MindMed Board of Directors"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy